Reuters: Business News: Valeant in talks to buy Actavis for over $13 billion: WSJ

Reuters: Business News Reuters.com is your source for breaking news, business, financial and investing news, including personal finance and stocks. Reuters is the leading global provider of news, financial information and technology solutions to the world's media, financial institutions, businesses and individuals.

Valeant in talks to buy Actavis for over $13 billion: WSJ Apr 26th 2013, 23:47 (Reuters) - Canada's biggest listed drug maker, Valeant Pharmaceuticals International Inc , is in talks to buy generic drugmaker Actavis Inc for more than $13 billion, Wall Street Journal reported, citing people familiar with the matter.

You are receiving this email because you subscribed to this feed at blogtrottr.com. If you no longer wish to receive these emails, you can unsubscribe from this feed, or manage all your subscriptions